详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Complete response to anti-PD1 therapy and chemotherapy in a patient with ALK-rearranged non-small cell lung cancer

0| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ ESCI

作者：

机构： [1]Univ Elect Sci & Technol, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Dept Med Oncol,Med Sch, Chengdu, Sichuan, Peoples R China [2]Third Hosp Mianyang, Sichuan Mental Hlth Ctr, Dept Pathol, Mianyang, Sichuan, Peoples R China [3]Third Hosp Mianyang, Sichuan Mental Hlth Ctr, Dept Oncol, Mianyang 621000, Sichuan, Peoples R China [4]Zhongjiang Peoples Hosp, Dept Gastroenterol, Deyang, Sichuan, Peoples R China

出处：

DOI：

ISSN：

关键词： Non-small cell lung cancer ALK rearrangement immunotherapy PD-1 PD-L1 chemotherapy

摘要：

Targeted therapies are effective in non-small cell lung cancer (NSCLC) patients with driver gene mutations. Chemotherapy combined with immunotherapy is also a common treatment strategy in lung cancer. However, in previous studies, patients with ALK (Anaplastic Lymphoma Kinase) rearranged had a low response to immune checkpoint inhibitor (ICI) and the role of immunotherapy in ALK-positive NSCLC patients is unclear. Here, we report a case of a young man with ALK rearranged who demonstrated a complete response to anti-PD1 combination with chemotherapy, which suggests some ALK-rearranged patients with high expression of PD-L1 may permanently benefit from immunotherapy.

语种：

WOS：

PubmedID：

JCR分区：

出版当年[2025]版：

无

最新[2023]版：

Q3 PATHOLOGY Q4 ONCOLOGY

影响因子： 1.2 最新[2023版] 1.3 最新五年平均 0 出版当年[2024版] 0 出版当年五年平均 0 出版前一年[2024版]

第一作者：

第一作者机构： [1]Univ Elect Sci & Technol, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Dept Med Oncol,Med Sch, Chengdu, Sichuan, Peoples R China

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]中国非小细胞肺癌免疫检查点抑制剂治疗专家共识(2019年版） [2]Significant metabolic alterations in non-small cell lung cancer patients by epidermal growth factor receptor-targeted therapy and PD-1/PD-L1 immunotherapy [3]结直肠癌pd-1和pd-l1信号通路及免疫治疗研究现状与进展 [4]PD-1/PD-L1在食管鳞状细胞癌中的表达及临床意义 [5]中国PD-1/PD-L1抑制剂治疗肺癌临床试验概况 [6]PD-1/PD-L1在肝细胞癌治疗中的研究进展 [7]The miR-23a/27a/24 - 2 cluster drives immune evasion and resistance to PD-1/PD-L1 blockade in non-small cell lung cancer [8]Current status and progress of PD-L1 detection: guiding immunotherapy for non-small cell lung cancer [9]PD-1/PD-L1抑制剂在妇科肿瘤的研究进展 [10]Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment